Related Experiment Video
Updated: Mar 25, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
3D-QSAR AND CONTOUR MAP ANALYSIS OF TARIQUIDAR ANALOGUES AS MULTIDRUG RESISTANCE PROTEIN-1 (MRP1) INHIBITORS
Prathusha Kakarla1, Madhuri Inupakutika2, Amith R Devireddy2
1Department of Biology, Eastern New Mexico University, Station 33, Portales, NM, 88130, USA.
Abstract:
One of the major obstacles to the successful chemotherapy towards several cancers is multidrug resistance of human cancer cells to anti-cancer drugs. An important contributor to multidrug resistance is the human multidrug resistance protein-1 transporter (MRP1), which is an efflux pump of the ABC (ATP binding cassette) superfamily. Thus, highly efficacious, third generation MRP1 inhibitors, like tariquidar analogues, are promising inhibitors of multidrug resistance and are under clinical trials. To maximize the efficacy of MRP1 inhibitors and to reduce systemic toxicity, it is important to limit the exposure of MRP1 inhibitors and anticancer drugs to normal tissues and to increase their co-localization with tumor cells. Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) associated with 3D-Quantitiative structure-activity relationship (3D-QSAR) studies were performed on a series of tariquidar analogues, as selective MDR modulators. Best predictability was obtained with CoMFA model r (non-cross-validated square of correlation coefficient) = 0.968, F value = 151.768 with five components, standard error of estimate = 0.107 while the CoMSIA yielded r = 0.982, F value = 60.628 with six components, and standard error of estimate = 0.154. These results indicate that steric, electrostatic, hydrophobic (lipophilic), and hydrogen bond donor substituents play significant roles in multidrug resistance modulation of tariquidar analogues upon MRP1. The tariquidar analogue and MRP1 binding and stability data generated from CoMFA and CoMSIA based 3D-contour maps may further aid in study and design of tariquidar analogues as novel, potent and selective MDR modulator drug candidates.
Insights
Multidrug resistance in cancer cells is a major chemotherapy obstacle. Tariquidar analogues, studied using 3D-QSAR, show promise as selective multidrug resistance modulators by targeting the MRP1 transporter.
Area of Science:
- Pharmacology and Medicinal Chemistry
- Cancer Biology
- Computational Chemistry
Background:
- Multidrug resistance (MDR) in human cancer cells significantly hinders chemotherapy efficacy.
- The human multidrug resistance protein-1 (MRP1) transporter, an ABC superfamily efflux pump, is a key contributor to MDR.
- Third-generation MRP1 inhibitors, such as tariquidar analogues, are under clinical investigation for MDR modulation.
Purpose of the Study:
- To investigate the structure-activity relationships of tariquidar analogues as selective MDR modulators.
- To identify key molecular features influencing the interaction of tariquidar analogues with MRP1.
- To guide the design of novel, potent, and selective MDR modulator drug candidates.
Main Methods:
- Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) were employed.
- 3D-Quantitative Structure-Activity Relationship (3D-QSAR) studies were performed on a series of tariquidar analogues.
- Predictive models were generated to analyze the contribution of various substituents to MDR modulation.
Main Results:
- CoMFA model achieved high predictability (r=0.968) and CoMSIA model showed excellent predictability (r=0.982).
- Steric, electrostatic, hydrophobic, and hydrogen bond donor substituents were identified as significant factors in MRP1 modulation by tariquidar analogues.
- 3D-contour maps from CoMFA and CoMSIA provided insights into tariquidar analogue-MRP1 binding and stability.
Conclusions:
- Tariquidar analogues demonstrate significant potential as selective MDR modulators.
- Understanding the role of specific substituents can optimize the design of next-generation MRP1 inhibitors.
- CoMFA and CoMSIA analyses are valuable tools for developing novel MDR modulator drug candidates.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
05:32Author Spotlight: Characterizing DNA G-Quadruplex by Bis-3-Chloropiperidine Based Chemical Mapping
Published on: May 12, 2023
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Quantitative Aspects of Drug-Receptor Interaction
Protein-Drug Binding: Determination Methods
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...